These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10160102)

  • 41. The role of combination therapy in achieving blood pressure control.
    Neutel JM
    Am J Manag Care; 1999 Jun; 5(7 Suppl):S463-8. PubMed ID: 10538855
    [No Abstract]   [Full Text] [Related]  

  • 42. [Therapy of hypertension 1996. Effectiveness, tolerance, cost-benefit aspects].
    Rahn KH
    Med Klin (Munich); 1996 Jun; 91(6):380-3. PubMed ID: 8767312
    [No Abstract]   [Full Text] [Related]  

  • 43. Public health value of fixed-dose combinations in hypertension.
    Ruilope LM; Burnier M; Muszbek N; Brown RE; Keskinaslan A; Ferber P; Harms G
    Blood Press Suppl; 2008 Jun; 1():5-14. PubMed ID: 18705530
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Analysis of pharmacologic costs in the treatment of arterial hypertension. Approximation to a cost-effectiveness study].
    Alonso Moreno FJ; García Palencia M; Laborda Peralta M; Hermoso López A; Lopez de Castro F
    Aten Primaria; 1998 May; 21(9):607-12. PubMed ID: 9677744
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Therapy of hypertension. Cost conscious prevention of complications].
    Kolloch RE
    MMW Fortschr Med; 2003 Nov; 145(47):64. PubMed ID: 14725042
    [No Abstract]   [Full Text] [Related]  

  • 46. Economic Evaluation of Pharmacists Tackling the Burden of Hypertension in Japan.
    Okada H; Johnston K; Nakayama T; Marra C; Tsuyuki RT
    Hypertension; 2019 Dec; 74(6):e54-e55. PubMed ID: 31607176
    [No Abstract]   [Full Text] [Related]  

  • 47. [The comparative assessment of the efficacy of hypotensive preparations in stage-II hypertension].
    Tiurin VP; Fursov AN; Gospodarenko AL; Liapkova NB; Orlov FA
    Voen Med Zh; 1997 Nov; 318(11):46-7. PubMed ID: 9461836
    [No Abstract]   [Full Text] [Related]  

  • 48. Impact of poorly controlled hypertension on healthcare resource utilization and cost.
    Paramore LC; Halpern MT; Lapuerta P; Hurley JS; Frost FJ; Fairchild DG; Bates D
    Am J Manag Care; 2001 Apr; 7(4):389-98. PubMed ID: 11310193
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of the Pharmacoeconomic Aspects in the Clinical Management of Hypertension.
    Degli Esposti L; Degli Esposti E
    High Blood Press Cardiovasc Prev; 2016 Jun; 23(2):151-4. PubMed ID: 27160719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adherence and health care costs with single-pill fixed-dose combinations in hypertension management.
    Hilleman DE
    J Manag Care Pharm; 2014 Jan; 20(1):93-100. PubMed ID: 24372463
    [No Abstract]   [Full Text] [Related]  

  • 52. Compliance with antihypertensive therapy: raising the bar of expectations.
    Rudd P
    Am J Manag Care; 1998 Jul; 4(7):957-66. PubMed ID: 10181995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial.
    van der Laan DM; Elders PJ; Boons CC; Bosmans JE; Nijpels G; Hugtenburg JG
    Trials; 2017 Jan; 18(1):29. PubMed ID: 28103948
    [TBL] [Abstract][Full Text] [Related]  

  • 54. First-line drugs for hypertension.
    Spence JD
    CMAJ; 2001 Jan; 164(2):176-8. PubMed ID: 11332306
    [No Abstract]   [Full Text] [Related]  

  • 55. [Medical economics of antihypertensive agents].
    Yamazaki T
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():285-8. PubMed ID: 16981557
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
    Linjer E; Hedner T; Jönsson B; Ekbom T; Lindholm LH; Dahlöf B; de Faire U; Scherstén B;
    Blood Press; 2005; 14(2):107-13. PubMed ID: 16036488
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic implications of evidence-based prescribing for hypertension: can better care cost less?
    Fischer MA; Avorn J
    JAMA; 2004 Apr; 291(15):1850-6. PubMed ID: 15100203
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Rational prescribing in patients with arterial hypertension].
    Torres Pacho JA; Mora Guío FJ; Charques Velasco E; Alonso Martínez MM
    Gac Sanit; 2002; 16(2):196-7; author reply 197. PubMed ID: 11958758
    [No Abstract]   [Full Text] [Related]  

  • 59. Defining the patient group for cost-effective withdrawal of antihypertensive therapy.
    Krakoff LR; Wassertheil-Smoller S
    Pharmacoeconomics; 1995 Mar; 7(3):221-8. PubMed ID: 10155311
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The cost of antihypertensive drug combinations].
    Buitrago F
    Med Clin (Barc); 1996 May; 106(17):677. PubMed ID: 8691916
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.